Rare cases of a brain-capillary leak syndrome called reversible posterior leukoencephalopathy syndrome have led to a revision in the Warnings and Adverse Reactions sections of the prescribing information for bevacizumab (Avastin, Genentech).
Rare cases of a brain-capillary leak syndrome called reversible posterior leukoencephalopathy syndrome have led to a revision in the Warnings and Adverse Reactions sections of the prescribing information for bevacizumab (Avastin, Genentech). The effect occurred at a rate of
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.